Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Review

Dual effect of oxidative stress on leukemia cancer induction and treatment

Authors: Udensi K Udensi, Paul B Tchounwou

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Oxidative stress (OS) has been characterized by an imbalance between the production of reactive oxygen species (ROS) and a biological system’s ability to repair oxidative damage or to neutralize the reactive intermediates including peroxides and free radicals. High ROS production has been associated with significant decrease in antioxidant defense mechanisms leading to protein, lipid and DNA damage and subsequent disruption of cellular functions. In humans, OS has been reported to play a role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease, Lou Gehrig’s disease, multiple sclerosis and Parkinson’s disease, as well as atherosclerosis, autism, cancer, heart failure, and myocardial infarction. Although OS has been linked to the etiology and development of chronic diseases, many chemotherapeutic drugs have been shown to exert their biologic activity through induction of OS in affected cells. This review highlights the controversial role of OS in the development and progression of leukemia cancer and the therapeutic application of increased OS and antioxidant approaches to the treatment of leukemia patients.
Appendix
Available only for authorised users
Literature
1.
2.
Kumar S, Yedjou CG, Tchounwou PB: Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res. 2014, 33: 42-PubMedCentralPubMedCrossRef
3.
Ristow M, Zarse K: How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Exp Gerontol. 2010, 45: 410-418.PubMedCrossRef
4.
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007, 39: 44-84.PubMedCrossRef
5.
Weinberg F, Chandel NS: Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci. 2009, 66: 3663-3673.PubMedCrossRef
6.
Lau AT, Wang Y, Chiu JF: Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem. 2008, 104: 657-667.PubMedCrossRef
7.
Renschler MF: The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer. 2004, 40: 1934-1940.PubMedCrossRef
8.
Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008, 68: 1777-1785.PubMedCrossRef
9.
Fried L, Arbiser JL: The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res. 2008, 21: 117-122.PubMedCrossRef
10.
Battisti V, Maders LD, Bagatini MD, Santos KF, Spanevello RM, Maldonado PA, Brulé AO, Araújo Mdo C, Schetinger MR, Morsch VM: Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem. 2008, 41: 511-518.PubMedCrossRef
11.
Farquhar MJ, Bowen DT: Oxidative stress and the myelodysplastic syndromes. Int J Hematol. 2003, 77: 342-350.PubMedCrossRef
12.
Sallmyr A, Fan J, Rassool FV: Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 2008, 270: 1-9.PubMedCrossRef
13.
Wilson JN, Pierce JD, Clancy RL: Reactive oxygen species in acute respiratory distress syndrome. Heart Lung. 2001, 30: 370-375.PubMedCrossRef
14.
Dugan LL, Quick KL: Reactive oxygen species and aging: evolving questions. Sci Aging Knowledge Environ. 2005, 2005: e20-CrossRef
15.
Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MP, Markesbery WR, Harris ME, Aksenov M, Aksenova M, Wu JF, Carney JM: Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer’s disease-associated amyloid beta peptide. Ann N Y Acad Sci. 1996, 786: 120-134.PubMedCrossRef
16.
Halliwell B: Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br J Exp Pathol. 1989, 70: 737-757.PubMedCentralPubMed
17.
Touyz RM: Reactive oxygen species and angiotensin II signaling in vascular cells – implications in cardiovascular disease. Braz J Med Biol Res. 2004, 37: 1263-1273.PubMedCrossRef
18.
Muhammad S, Bierhaus A, Schwaninger M: Reactive oxygen species in diabetes-induced vascular damage, stroke, and Alzheimer’s disease. J Alzheimers Dis. 2009, 16: 775-785.PubMed
19.
Di VF: New pathways for reactive oxygen species generation in inflammation and potential novel pharmacological targets. Curr Pharm Des. 2004, 10: 1647-1652.CrossRef
20.
Moulton PJ: Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci. 1996, 53: 317-324.PubMed
21.
Bolanos JP, Moro MA, Lizasoain I, Almeida A: Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. Adv Drug Deliv Rev. 2009, 61: 1299-1315.PubMedCrossRef
22.
Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114: 1752-1761.PubMedCentralPubMedCrossRef
23.
Tieu K, Ischiropoulos H, Przedborski S: Nitric oxide and reactive oxygen species in Parkinson’s disease. IUBMB Life. 2003, 55: 329-335.PubMedCrossRef
24.
Kinnula VL, Fattman CL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med. 2005, 172: 417-422.PubMedCentralPubMedCrossRef
25.
Gelderman KA, Hultqvist M, Olsson LM, Bauer K, Pizzolla A, Olofsson P, Holmdahl R: Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Antioxid Redox Signal. 2007, 9: 1541-1567.PubMedCrossRef
26.
Jeremy JY, Shukla N, Muzaffar S, Handley A, Angelini GD: Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol. 2004, 2: 229-236.PubMedCrossRef
27.
Maraldi T, Prata C, Vieceli Dalla Sega F, Caliceti C, Zambonin L, Fiorentini D, Hakim G: NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res. 2009, 43: 1111-1121.PubMedCrossRef
28.
Naughton R, Quiney C, Turner SD, Cotter TG: Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia. 2009, 23: 1432-1440.PubMedCrossRef
29.
Arnold RS, He J, Remo A, Ritsick D, Yin-Goen Q, Lambeth JD, Datta MW, Young AN, Petros JA: Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1. Am J Pathol. 2007, 171: 2021-2032.PubMedCentralPubMedCrossRef
30.
Wu WS, Wu JR, Hu CT: Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev. 2008, 27: 303-314.PubMedCrossRef
31.
Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009, 8: 579-591.PubMedCrossRef
32.
Gorrini C, Harris IS, Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013, 12: 931-947.PubMedCrossRef
33.
34.
Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004, 266: 37-56.PubMedCrossRef
35.
36.
Finkel T, Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature. 2000, 408: 239-247.PubMedCrossRef
37.
38.
39.
Halliwell B, Gutteridge J: Free radicals in biology and medicine. 1999, Clarendon, Oxford, 3
40.
Niklowitz P, Wiesel T, Andler W, Menke T: Coenzyme Q10 concentration in the plasma of children suffering from acute lymphoblastic leukaemia before and during induction treatment. Biofactors. 2007, 29: 83-89.PubMedCrossRef
41.
Liu CX, Zhou HC, Yin QQ, Wu YL, Chen GQ: Targeting peroxiredoxins against leukemia. Exp Cell Res. 2013, 319: 170-176.PubMedCrossRef
42.
Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006, 160: 1-40.PubMedCrossRef
43.
Devi GS, Prasad MH, Saraswathi I, Raghu D, Rao DN, Reddy PP: Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias. Clin Chim Acta. 2000, 293: 53-62.PubMedCrossRef
44.
Poli G, Leonarduzzi G, Biasi F, Chiarpotto E: Oxidative stress and cell signalling. Curr Med Chem. 2004, 11: 1163-1182.PubMedCrossRef
45.
Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, Utsumi K: Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem. 2003, 10: 2495-2505.PubMedCrossRef
46.
Conner EM, Grisham MB: Inflammation, free radicals, and antioxidants. Nutrition. 1996, 12: 274-277.PubMedCrossRef
47.
48.
49.
Loschen G, Flohe L, Chance B: Respiratory chain linked H(2)O(2) production in pigeon heart mitochondria. FEBS Lett. 1971, 18: 261-264.PubMedCrossRef
50.
Li C, Jackson RM: Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol. 2002, 282: C227-C241.PubMedCrossRef
51.
Gupta M, Dobashi K, Greene EL, Orak JK, Singh I: Studies on hepatic injury and antioxidant enzyme activities in rat subcellular organelles following in vivo ischemia and reperfusion. Mol Cell Biochem. 1997, 176: 337-347.PubMedCrossRef
52.
Fransen M, Nordgren M, Wang B, Apanasets O: Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. Biochim Biophys Acta. 1822, 2012: 1363-1373.
53.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med. 2010, 49: 1603-1616.PubMedCentralPubMedCrossRef
54.
Görlach A, Berchner-Pfannschmidt U, Wotzlaw C, Cool RH, Fandrey J, Acker H, Jungermann K, Kietzmann T: Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1. Thromb Haemost. 2003, 89: 926-935.PubMed
55.
Velasco-Hernandez T, Hyrenius-Wittsten A, Rehn M, Bryder D, Cammenga J: HIF-1alpha can act as a tumor suppressor gene in murine Acute Myeloid Leukemia. Blood. 2014, 124 (24): 3597-3607.PubMedCrossRef
56.
Surh YJ, Kundu JK, Na HK, Lee JS: Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr. 2005, 135: 2993S-3001S.PubMed
57.
58.
Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB: Deciphering AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle. 2007, 6: 2633-2639.PubMedCrossRef
59.
Browatzki M, Larsen D, Pfeiffer CA, Gehrke SG, Schmidt J, Kranzhofer A, Katus HA, Kranzhofer R: Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res. 2005, 42: 415-423.PubMedCrossRef
60.
Saito T, Itoh H, Yamashita J, Doi K, Chun TH, Tanaka T, Inoue M, Masatsugu K, Fukunaga Y, Sawada N, Sakaguchi S, Arai H, Tojo K, Tajima N, Hosoya T, Nakao K: Angiotensin II suppresses growth arrest specific homeobox (Gax) expression via redox-sensitive mitogen-activated protein kinase (MAPK). Regul Pept. 2005, 127: 159-167.PubMedCrossRef
61.
Gorski DH, LePage DF, Patel CV, Copeland NG, Jenkins NA, Walsh K: Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol. 1993, 13: 3722-3733.PubMedCentralPubMedCrossRef
62.
Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO: Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis. 2013, 4: e516-PubMedCentralPubMedCrossRef
63.
Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S: CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARgamma signaling. J Clin Invest. 2013, 123: 299-314.PubMedCentralPubMedCrossRef
64.
Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, Huang G, Di Giandomenico S, Koff A, Nimer SD: The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle. 2009, 8: 3120-3124.PubMedPubMedCentralCrossRef
65.
Breccia M, Alimena G: Efficacy and safety of deferasirox in myelodysplastic syndromes. Ann Hematol. 2013, 92: 863-870.PubMedCrossRef
66.
Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z: STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci U S A. 2010, 107: 2902-2907.PubMedCentralPubMedCrossRef
67.
Cadenas E, Davies KJ: Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. 2000, 29: 222-230.PubMedCrossRef
68.
Rizzo AM, Berselli P, Zava S, Montorfano G, Negroni M, Corsetto P, Berra B: Endogenous antioxidants and radical scavengers. Adv Exp Med Biol. 2010, 698: 52-67.PubMedCrossRef
69.
Burton GW, Ingold KU: Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci. 1989, 570: 7-22.PubMedCrossRef
70.
Cai Y, Sun M, Corke H: Antioxidant activity of betalains from plants of the amaranthaceae. J Agric Food Chem. 2003, 51: 2288-2294.PubMedCrossRef
71.
Zheng W, Wang SY: Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem. 2001, 49: 5165-5170.PubMedCrossRef
72.
Oberley LW, Buettner GR: Role of superoxide dismutase in cancer: a review. Cancer Res. 1979, 39: 1141-1149.PubMed
73.
Manoharan S, Kolanjiappan K, Kayalvizhi M: Enhanced lipid peroxidation and impaired enzymic antioxidant activities in the erythrocytes of patients with cervical carcinoma. Cell Mol Biol Lett. 2004, 9: 699-707.PubMed
74.
Oktyabrsky ON, Smirnova GV: Redox regulation of cellular functions. Biochemistry (Mosc). 2007, 72: 132-145.CrossRef
75.
Catalani S, Carbonaro V, Palma F, Arshakyan M, Galati R, Nuvoli B, Battistelli S, Canestrari F, Benedetti S: Metabolism modifications and apoptosis induction after Cellfood administration to leukemia cell lines. J Exp Clin Cancer Res. 2013, 32: 63-PubMedCentralPubMedCrossRef
76.
Chang C, Zhu YQ, Mei JJ, Liu SQ, Luo J: Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. J Exp Clin Cancer Res. 2010, 29: 145-PubMedCentralPubMedCrossRef
77.
Yamamoto JF, Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008, 19: 379-390.PubMedCrossRef
78.
79.
Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD: Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. Leuk Res. 2014, 38: 95-102.PubMedCrossRef
80.
81.
82.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380: 2095-2128.PubMedCrossRef
83.
Mathers CD, Shibuya K, Boschi-Pinto C, Lopez AD, Murray CJ: Global and regional estimates of cancer mortality and incidence by site: I. Application of regional cancer survival model to estimate cancer mortality distribution by site. BMC Cancer. 2002, 2: 36-PubMedCentralPubMedCrossRef
84.
Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002, 100: 2292-2302.PubMedCrossRef
85.
86.
Kennedy JA, Barabe F: Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia. 2008, 22: 2029-2040.PubMedCrossRef
87.
88.
Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, Ma J, Minden MD, Downing JR, Dick JE: Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011, 469: 362-367.PubMedCrossRef
89.
90.
Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008, 22: 1308-1319.PubMedCrossRef
91.
Niemeyer CM, Kratz CP, Hasle H: Pediatric myelodysplastic syndromes. Curr Treat Options Oncol. 2005, 6: 209-214.PubMedCrossRef
92.
Germing U, Gattermann N, Strupp C, Aivado M, Aul C: Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000, 24: 983-992.PubMedCrossRef
93.
Bhatia S, Neglia JP: Epidemiology of childhood acute myelogenous leukemia. J Pediatr Hematol Oncol. 1995, 17: 94-100.PubMedCrossRef
94.
Austin C: Does oxidative damage contribute to the generation of leukemia?. Leuk Res. 2009, 33: 1297-PubMedCrossRef
95.
Zhou F, Zhang W, Wei Y, Zhou D, Su Z, Meng X, Hui L, Tian W: The changes of oxidative stress and human 8-hydroxyguanine glycosylase1 gene expression in depressive patients with acute leukemia. Leuk Res. 2007, 31: 387-393.PubMedCrossRef
96.
Troy JD, Atallah E, Geyer JT, Saber W: Myelodysplastic syndromes in the United States: an update for clinicians. Ann Med. 2014, 46 (5): 283-289.PubMedCrossRef
97.
Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D’Adamio L, Hersh LB, Reinherz EL: Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (“enkephalinase”): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A. 1989, 86: 297-301.PubMedCentralPubMedCrossRef
98.
Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z: CYP1A1 MspI polymorphism and acute myeloid leukemia risk: meta-analyses based on 5018 subjects. J Exp Clin Cancer Res. 2012, 31: 62-PubMedCentralPubMedCrossRef
99.
Linker CA: Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant. 2003, 31: 731-738.PubMedCrossRef
100.
Marcus RE, Matutes E, Drysdale H, Catovsky D: Phenotypic conversion of TdT+ adult AML to CALLA+ ALL. Scand J Haematol. 1985, 35: 343-347.PubMedCrossRef
101.
Smits EL, Berneman ZN, Van Tendeloo VF: Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009, 14: 240-252.PubMedCrossRef
102.
Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, Tedeschi A, Vismara E, Morra E: Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res. 2008, 32: 1221-1227.PubMedCrossRef
103.
Faderl S, Kantarjian HM, Talpaz M: Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park). 1999, 13: 169-180.
104.
Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983, 306: 277-280.PubMedCrossRef
105.
Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243: 290-293.PubMedCrossRef
106.
107.
Padron E, Komrokji R, List AF: The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014, 12: 172-178.PubMed
108.
Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 2008, 22: 1335-1342.PubMedCrossRef
109.
Pardanani A, Tefferi A: Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004, 104: 1931-1939.PubMedCrossRef
110.
111.
Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A, Jones D, Mahmud S, Meloche C, Sabloff M, Sharif I, Storring J, Turner D, Seftel MD: Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014, 166 (5): 660-666.PubMedCrossRef
112.
Rowley JD, Golomb HM, Dougherty C: 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977, 1: 549-550.PubMedCrossRef
113.
Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993, 74: 423-431.PubMedCrossRef
114.
Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP: PML is essential for multiple apoptotic pathways. Nat Genet. 1998, 20: 266-272.PubMedCrossRef
115.
Quignon F, De BF, Koken M, Feunteun J, Ameisen JC, de Thé H: PML induces a novel caspase-independent death process. Nat Genet. 1998, 20: 259-265.PubMedCrossRef
116.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008, 111: 5446-5456.PubMedCentralPubMedCrossRef
117.
Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D: Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014, 123: 2663-2672.PubMedCrossRef
118.
Lo CF, Nervi C, Avvisati G, Mandelli F: Acute promyelocytic leukemia: a curable disease. Leukemia. 1998, 12: 1866-1880.CrossRef
119.
Chlapek P, Redova M, Zitterbart K, Hermanova M, Sterba J, Veselska R: Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study. J Exp Clin Cancer Res. 2010, 29: 45-PubMedCentralPubMedCrossRef
120.
Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003, 98: 1337-1354.PubMedCrossRef
121.
Espérou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP, Milpied N, Cahn JY, Faucher C, Bourhis JH, Michallet M, Tanguy ML, Vernant JP, Gabert J, Bordigoni P, Ifrah N, Baruchel A, Dombret H, French Bone Marrow Transplantation: A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant. 2003, 31: 909-918.PubMedCrossRef
122.
Hu Y, Gu X, Li R, Luo Q, Xu Y: Glycogen synthase kinase-3beta inhibition induces nuclear factor-kappaB-mediated apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin Cancer Res. 2010, 29: 154-PubMedCentralPubMedCrossRef
123.
Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A: Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010, 28: 3644-3652.PubMedCrossRef
124.
Chavez JC, Sahakian E, Pinilla-Ibarz J: Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013, 8: 37-45.PubMedCentralPubMed
125.
126.
127.
Hamblin AD, Hamblin TJ: The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008, 87: 49-62.PubMedCrossRef
128.
Hjalmar V, Kimby E, Matutes E, Sundstrom C, Wallvik J, Hast R: Atypical lymphocytes in B-cell chronic lymphocytic leukemia and trisomy 12 studied by conventional staining combined with fluorescence in situ hybridization. Leuk Lymphoma. 2000, 37: 571-576.PubMedCrossRef
129.
Parmar S, Patel K, Pinilla-Ibarz J: Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2014, 39: 483-519.
130.
Zhang X, Machii T, Matsumura I, Ezoe S, Kawasaki A, Tanaka H, Ueda S, Sugahara H, Shibayama H, Mizuki M, Kanakura Y: Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol. 2003, 77: 263-273.PubMedCrossRef
131.
Wrede JE, Sundram U, Kohler S, Cherry AM, Arber DA, George TI: Fluorescence in situ hybridization investigation of cutaneous lesions in acute promyelocytic leukemia. Mod Pathol. 2005, 18: 1569-1576.PubMed
132.
Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001, 61: 4365-4370.PubMed
133.
Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996, 313 (Pt 1): 17-29.PubMedCentralPubMedCrossRef
134.
Cerutti PA, Trump BF: Inflammation and oxidative stress in carcinogenesis. Cancer Cells. 1991, 3: 1-7.PubMed
135.
Dreher D, Junod AF: Role of oxygen free radicals in cancer development. Eur J Cancer. 1996, 32A: 30-38.PubMedCrossRef
136.
137.
Adler V, Yin Z, Tew KD, Ronai Z: Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 1999, 18: 6104-6111.PubMedCrossRef
138.
Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT: Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med. 2001, 30: 1286-1292.PubMedCrossRef
139.
Nishiura T, Suzuki K, Kawaguchi T, Nakao H, Kawamura N, Taniguchi M, Kanayama Y, Yonezawa T, Iizuka S, Taniguchi N: Elevated serum manganese superoxide dismutase in acute leukemias. Cancer Lett. 1992, 62: 211-215.PubMedCrossRef
140.
Silber R, Farber CM, Papadopoulos E, Nevrla D, Liebes L, Bruck M, Brown R, Canellakis ZN: Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood. 1992, 80: 2038-2043.PubMed
141.
Flora SJ: Structural, chemical and biological aspects of antioxidants for strategies against metal and metalloid exposure. Oxid Med Cell Longev. 2009, 2: 191-206.PubMedCentralPubMedCrossRef
142.
143.
Moore N, Lyle S: Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. J Oncol. 2011, 2011: Article ID: 396076-CrossRef
144.
Augustin W, Wiswedel I, Noack H, Reinheckel T, Reichelt O: Role of endogenous and exogenous antioxidants in the defence against functional damage and lipid peroxidation in rat liver mitochondria. Mol Cell Biochem. 1997, 174: 199-205.PubMedCrossRef
145.
Guachalla LM, Rudolph KL: ROS induced DNA damage and checkpoint responses: influences on aging?. Cell Cycle. 2010, 9: 4058-4060.PubMedCrossRef
146.
Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008, 123: 1227-1239.PubMedCrossRef
147.
Hole PS, Darley RL, Tonks A: Do reactive oxygen species play a role in myeloid leukemias?. Blood. 2011, 117: 5816-5826.PubMedCrossRef
148.
Schuurman AG, Goldbohm RA, Brants HA, van den Brandt PA: A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control. 2002, 13: 573-582.PubMedCrossRef
149.
Fleischauer AT, Olson SH, Mignone L, Simonsen N, Caputo TA, Harlap S: Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. Nutr Cancer. 2001, 40: 92-98.PubMedCrossRef
150.
Rodrigues MS, Reddy MM, Sattler M: Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal. 2008, 10: 1813-1848.PubMedCrossRef
151.
Yu C, Rahmani M, Dent P, Grant S: The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res. 2004, 295: 555-566.PubMedCrossRef
152.
153.
Yedjou CG, Tchounwou PB: In vitro assessment of oxidative stress and apoptotic mechanisms of garlic extract in the treatment of acute promyelocytic leukemia. J Cancer Sci Ther. 2012, 2012: 6-PubMed
154.
Townsend DM, Findlay VL, Tew KD: Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol. 2005, 401: 287-307.PubMedCrossRef
155.
Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M, Yamaji S, Ueda A, Tomita N, Fujita H, Ishigatsubo Y: Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci. 2010, 101: 1409-1416.PubMedCrossRef
156.
Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008, 112: 1912-1922.PubMedCentralPubMedCrossRef
157.
Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P: Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008, 22: 1191-1199.PubMedCentralPubMedCrossRef
158.
Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH: Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006, 107: 2501-2506.PubMedCentralPubMedCrossRef
159.
Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007, 104: 12288-12293.PubMedCentralPubMedCrossRef
160.
Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003, 278: 37832-37839.PubMedCrossRef
161.
Wang J, Li L, Cang H, Shi G, Yi J: NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res. 2008, 32: 429-436.PubMedCrossRef
162.
Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le BM, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, de Thé H: PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010, 18: 88-98.PubMedCrossRef
163.
Doudican NA, Bowling B, Orlow SJ: Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res. 2010, 34: 229-234.PubMedCentralPubMedCrossRef
164.
Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol. 2010, 3: 28-PubMedCentralPubMedCrossRef
165.
Rogers CS, Yedjou CG, Sutton DJ, Tchounwou PB: Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells. Exp Hematol Oncol. 2014, 3: 9-PubMedCentralPubMedCrossRef
166.
Yedjou C, Thuisseu L, Tchounwou C, Gomes M, Howard C, Tchounwou P: Ascorbic acid potentiation of arsenic trioxide anticancer activity against acute promyelocytic leukemia. Arch Drug Inf. 2009, 2: 59-65.PubMedCentralPubMedCrossRef
167.
Yedjou CG, Rogers C, Brown E, Tchounwou PB: Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells. J Biochem Mol Toxicol. 2008, 22: 85-92.PubMedCentralPubMedCrossRef
168.
Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, Hirose K, Kiyosawa K, Kamata T: Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene. 2006, 25: 3699-3707.PubMedCrossRef
169.
Conklin KA: Cancer chemotherapy and antioxidants. J Nutr. 2004, 134: 3201S-3204S.PubMed
170.
Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H: Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res. 1995, 19: 605-612.PubMedCrossRef
Metadata
Title
Dual effect of oxidative stress on leukemia cancer induction and treatment
Authors
Udensi K Udensi
Paul B Tchounwou
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-014-0106-5

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue

Research

Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model

Research

Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas

Research

p38α MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine

Research

Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents

Research

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Research

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits